Ana M. Bajo - Concepedia

Concepedia

Author

Ana M. Bajo

Universidad de Alcalá ORCID

Also Known As

A BAJO, A Bajo, A M Bajo, A. Bajo, A. Bajo-Chueca, A. M. Bajo, A.M. Bajo, A.M. Bajo-Chueca, Alfred Bajo, Ana Bajo

83

Publications

1.4K

Citations

24

H-Index

52

Concepts

All Affiliations

Universidad de Alcalá Hospital Universitario Príncipe de Asturias University of Miami South Florida Veterans Affairs Foundation for Research and Education Tulane University

AM

About

Ana M. Bajo is an author at Universidad de Alcalá specializing in medicine, pharmacology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	34	865
2	Cell Biology	9	9	295
3	Natural Sciences	2	2	29
4	Biochemistry	2	2	28
5	Chemistry	1	1	15

Ana M. Bajo

×

48

Publications

1.4K

Citations

24

H-Index

	Year	Citations
Fibroblasts From the Transversalis Fascia of Young Patients With Direct Inguinal Hernias Show Constitutive MMP-2 Overexpression Juan M. Bellón, Ana M. Bajo, Natalio Garcı́a-Honduvilla, Annals of Surgery	2001	125
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers Markus Letsch, Andrew V. Schally, Rebeca Busto, Proceedings of the National Academy of Sciences UrologyOncologyGrowth Hormone-Independent Prostate CancersHuman Growth	2003	71
Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells Ana Valdehíta, Ana M. Bajo, Andrew V. Schally, Molecular and Cellular Endocrinology ImmunologyBreast CancerVasoactive Intestinal PeptideMedicineCell Biology	2008	56
Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer Ana Valdehíta, Ana M. Bajo, Ana B. Fernández‐Martínez, Peptides Gastrointestinal Peptide HormoneSignal TransductionReceptor (Biochemistry)Neuropeptide ReceptorHuman Breast Cancer	2010	53
Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Ana M. Bajo, Andrew V. Schally, Gábor Halmos, PubMed	2003	51
Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers Ana M. Bajo, Andrew V. Schally, Kate Groot, British Journal of Cancer	2004	45
Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c- <i>jun</i> and c- <i>fos</i> oncogenes Ana M. Bajo, Andrew V. Schally, Magdalena Krupa, Proceedings of the National Academy of Sciences Breast OncologyBn/grp AntagonistsImmunologyCancer BiologyMammary Gland Development	2002	41
Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats Judit Horváth, Ana M. Bajo, Andrew V. Schally, Proceedings of the National Academy of Sciences	2002	41
Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas Károly Szepesházi, Andrew V. Schally, Attila Nagy, Cancer	2003	38
Hydrogen Bonding and Anticancer Properties of Water‐Soluble Chiral <i>p</i>‐Cymene Ru<sup>II</sup> Compounds with Amino‐Oxime Ligands Yosra Benabdelouahab, Laura Muñoz‐Moreno, Malgorzata Frik, European Journal of Inorganic Chemistry	2015	37

Page 1